Compromised chronic efficacy of a Glucokinase Activator AZD1656 in mouse models for common human GCKR variants
B. E. Ford, S. S. Chachra, A. Alshawi, F. Oakley, R. J. Fairclough, D. M. Smith, D. Tiniakos, L. Agius
This study shows that GKRP deficiency in mouse models reduces the long-term efficacy of the GKA AZD1656 and increases liver lipid accumulation.
bioRxiv · Jul 24, 2024 · PreprintPharmacology & Toxicology